IHC antibody | Expected result | ||
Paget's disease of the breast (PDB) | Malignant melanoma | Squamous carcinoma in situ (Bowen's disease) | |
CK7 | Positive-diffuse | Negative | Negative/focal positive |
CEA polyclonal | Positive | Negative | Negative/rare positive |
p63 | Negative* | Negative | Positive |
SOX10¶ | Negative | Positive | Negative |
Additional markers that may be useful additions to the above IHC antibodies | |||
Mart-1 (Melan A)¶ | Negative | Positive | Negative |
S-100¶ | Negative/weak positive | Positive/rare negative | Negative |
EMA | Positive | Negative | Positive |
HER2 | PositiveΔ | Negative | Negative |
HMWCK | Negative* | Negative | Positive |
IHC: immunohistochemical; CK7: cytokeratin 7; CEA: carcinoembryonic antigen; EMA: epithelial membrane antigen; HMWCK: high-molecular-weight cytokeratin (eg, 34betaE12 or CK5/6).
* Triple-negative breast cancer (TNBC) expresses p63 and HMWCK.
¶ Dermal and intraepithelial melanocytes will express SOX10, Mart-1, and S-100.
Δ PDB is usually (80 to 90%) HER2 positive but may be estrogen receptor positive or TNBC in a low proportion of cases.Do you want to add Medilib to your home screen?